Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
48.37
+1.81 (3.89%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 49, with a low estimate of 30 and a high estimate of 65. The average target predicts an increase of 1.30% from the current stock price of 48.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for KYMR stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 4 | 5 | 5 |
| Hold | 5 | 5 | 6 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $52 → $56 | Buy | Maintains | $52 → $56 | +15.77% | Sep 27, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $60 | Buy | Initiates | $60 | +24.04% | Sep 9, 2024 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $65 | Hold → Buy | Upgrades | $65 | +34.38% | Aug 26, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $34 → $45 | Hold | Maintains | $34 → $45 | -6.97% | Aug 14, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $30 → $38 | Hold | Maintains | $30 → $38 | -21.44% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
57.75M
from 78.59M
Decreased by -26.51%
Revenue Next Year
69.21M
from 57.75M
Increased by 19.83%
EPS This Year
-3.01
from -2.52
EPS Next Year
-3.32
from -3.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 78.8M | 154.4M | 284.6M | ||
| Avg | 57.8M | 69.2M | 73.8M | ||
| Low | 41.2M | 14.1M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.2% | 167.3% | 311.2% | ||
| Avg | -26.5% | 19.8% | 6.6% | ||
| Low | -47.6% | -75.6% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.21 | -1.74 | -1.62 | ||
| Avg | -3.01 | -3.32 | -3.41 | ||
| Low | -3.35 | -4.24 | -5.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.